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Abstract
Background: Patient stratification to identify subtypes with different disease manifestations, severity, and expected
survival time is a critical task in cancer diagnosis and treatment. While stratification approaches using various
biomarkers (including high-throughput gene expression measurements) for patient-to-patient comparisons have been
successful in elucidating previously unseen subtypes, there remains an untapped potential of incorporating various
genotypic and phenotypic data to discover novel or improved groupings.
Methods: Here, we present HOCUS, a unified analytical framework for patient stratification that uses a community
detection technique to extract subtypes out of sparse patient measurements. HOCUS constructs a patient-to-patient
network from similarities in the data and iteratively groups and reconstructs the network into higher order clusters.
We investigate the merits of using higher-order correlations to cluster samples of cancer patients in terms of their
associations with survival outcomes.
Results: In an initial test of the method, the approach identifies cancer subtypes in mutation data of glioblastoma,
ovarian, breast, prostate, and bladder cancers. In several cases, HOCUS provides an improvement over using the
molecular features directly to compare samples. Application of HOCUS to glioblastoma images reveals a size and
location classification of tumors that improves over human expert-based stratification.
Conclusions: Subtypes based on higher order features can reveal comparable or distinct groupings. The distinct
solutions can provide biologically- and treatment-relevant solutions that are just as significant as solutions based
on the original data.
Keywords: Molecular subtyping, Community detection, MRI, Magnetic resonance imaging, Clustering, Mutation,
Cancer
Background
Expression-based subtypes have shown to be of
tremendous use in predicting patient outcomes (e.g.
PAM50 and MammaPrint subtypes for breast cancer
prognosis) [1]. Most recently, transcriptome-wide RNA
sequencing data or other high-throughput measure-
ments have been used to segregate patient samples,
which in turn has led to suggestions for changes in
treatment of many cancers [2].
Both the sparsity of mutations and mutual exclusivity
common in mutation profiles (within the same molecu-
lar pathways) [3] present challenges in the use of
somatic variants for subtyping because similarities com-
puted from the original mutation events lack specificity
and robustness, due to the small number of overlapping
events between any two samples. Subtyping patients
based on magnetic resonance (MR) imaging data has
shown promise (see [4] for a recent example). In such
studies, the sparseness of anatomical/spatial MR image
data, resulting from tumors occupying only a fraction
of the imaged brain, can create issues for sample
clustering.
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In this work, we evaluate the use of “higher–order”
similarity measures between the samples to identify
biologically relevant subtypes. Intuitively, higher–orders
compare two samples based on how similar their sample
“neighborhoods” are to one another rather than using
the original data. Comparing neighbors can provide a
broader perspective on what might otherwise appear to
be a coincident similarity: a low level of overlap between
sparse feature sets may be relatively specific for a
particular subset of samples. To illustrate, consider
the toy network shown in Fig. 1. A first-order net-
work links any two samples with some minimum
first-order similarity. A second-order network then
links samples with overlapping neighborhoods in the
first-order network. Repetition of this procedure generates
higher-order networks from a lower-order version, that
could reveal community structure. By the third order, the
three communities emerge despite the fact that the
original features are only weakly associated with the
ground truth clusters.
We use such a similarity transformation, here referred
to as Higher-Order Correlations to Uncover Subtypes
(HOCUS), and show that HOCUS enhances the detection
of biologically-relevant clusters of patients for several
Cancer Genome Atlas (TCGA) cohorts. HOCUS is
applied to both categorical and ordinal data modalities,
using mutation and copy number data. In addition, we
apply HOCUS to Gadolinium- based contrast-enhanced
T1-weighted preoperative axial MRI data and establish links
between MR image features and patient overall survival.
(a)
(b)
Fig. 1 a Social network approach to clustering patient samples. First we transform/encode the mutation/voxel data, then compute all patient–patient
similarities. At each order of similarities, clustering is based on similarities in that order, resulting in different clustering solutions. Shown
here from left to right: features, 1st-order, 2nd-order, 3rd-order, ‘true’ communities. Note that links between the same sample but different
orders are not shown (e.g. A always has a strong self link), but are used in the similarity calculations. b Flow diagram of HOCUS analysis:
Feature data (such as imaging voxels or mutations are supplied to HOCUS to generate higher-order features from which sample-sample
similarities are calculated. The HOCUS order is selected by comparing sample-sample similarity kernels with an external criterion. Clustering is then
done followed by survival and downstream analyses
Graim et al. BMC Medical Genomics  (2017) 10:20 Page 2 of 14
We looked for inspiration from fields with similar
data, such as social network analysis. Detecting commu-
nity structure is an important problem in the study of
many different types of networks including social (e.g.
connected friends), online (linked web pages), and mo-
lecular (regulatory gene signaling). In these applications,
communities represent sets of densely connected nodes
within a larger set of nodes in a network. Cliques of
friends with shared interests or a gene module repre-
senting the shared function of genes in a biological
pathway are examples of such communities.
Community detection techniques have so far been
under-utilized for the purpose of subtyping patients
based on shared genomic- and image-based events. Yet
the application is straightforward – the data can be
converted readily into a network of patient samples using
sample-sample similarities. Mutations and MR images are
examples of sparse data, since few mutation events are
shared between patients and since the relative ratio of
tumor to normal tissue in the brain means that most
regions are tumor-free and so patient tumors are rarely in
the same location as other patient tumors. We asked
whether higher-order comparisons could boost perform-
ance when clustering these data. We find several cases in
which the HOCUS community detection approach identi-
fies biologically meaningful patient subtypes that can be
distinct from those identified using the direct features.
Methods
Overview of HOCUS clustering
HOCUS uses a technique from network analysis in
which samples are compared based on their neighbor-
hood similarity [5–7] and can be pictured as the con-
struction of progressively higher-order networks (Fig. 1).
Features are somatic mutations, copy number events, or
3D MR brain images of patients. Sample-sample similar-
ities were calculated using an appropriately chosen simi-
larity metric (Additional file 1: Figure S1, Section 0.0.2)
that can be viewed as a sample-by-sample network.
Higher-order similarities were derived from lower-order
similarities by treating the lower-order similarities com-
puted at step k − 1 as the features used to compute new
similarities at step k, similar to Yu et al. [8] and Yu et al.
[9], and to multiplying a network adjacency matrix to
itself one or more times in order to reveal connected
components linked by reachable paths. The samples can
be clustered using either the original features (i.e. use
first-order similarities) or features derived from higher-
order similarities, identifying groups of patients having a
higher proportion of transitive relations.
MR images
MR Imaging data were downloaded from the Cancer
Imaging Archive (www.cancerimagingarchive.net), and
were processed using Slicer [10]. Tumor location was
extracted from T1 anatomic MR images as previously
described [4]. Patient tumor was identified in the MR
images by having two experts delineate tumors’ regions
of interest, were registered to a common coordinate
space of a brain atlas along with anatomical T1 brain
images to obtain registered tumor ROIs, and then
feeding through the image-processing pipeline devel-
oped in an earlier paper by some of the current authors
[4]. This results in a per-patient 3-dimensional binary
matrix of tumor-containing and tumor-free voxels (3-
dimensional pixel) in the brain. Each 1 mm MR image
slice was rotated and aligned to a brain atlas (Montreal
Neurological Institute 152 [11]), to make voxels com-
parable between patients.
Mutations
Mutation and copy number data were downloaded from
Firehose (firebrowse.org); BRCA, GBM, and OV data
were downloaded March 18,2015; BLCA data were
downloaded Nov 9, 2015; and PRAD data were down-
loaded March 4, 2015. Only non-silent mutations were
retained for mutation-based analyses. In other words,
mutations in locations that were predicted as deletions,
insertion, splice-site, missense, or nonsense mutations,
were kept. These data were recorded into a binary-
valued patients-by-genes matrix. Only genes with at least
one non-silent mutation within the cohort and patients
with at least one non-silent mutation were represented
in the matrix.
Copy number
GISTIC2 [12] copy number variation data was down-
loaded from Firehose (firebrowse.org). Sample-sample
similarities were derived from Hamming distances
computed on the GISTIC integer-valued copy number
estimates ([−2,−1, 0, 1, 2]). Thus any identical copy
number values between tumor genomes are considered
a match in the similarity calculation.
Visualization of conditional densities
To visualize the association between feature- and
survival-based measures, we plotted the proportion of
sample pairs with similarities in both metric spaces. If
the distribution of survival similarities for sample pairs
changes as a function of the feature-derived similarities,
it suggests that the feature-based metric carries
outcome-relevant information. For example, if we re-
strict the pairs to those with high kernel similarity in
mutation space and we observe that there are more pairs
with similar survival compared to the background (or to
pairs with low mutation-based similarity) it would indi-
cate mutation-based similarity carried information about
survival outcome. To view such a dependency, we group
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sample pairs into bins of approximately equal feature-
based similarity. Then, for each bin, we plot the distribu-
tion of outcome similarities, shown along the left-hand
side of each conditional density plot. A distribution that
changes significantly across the bins reflects an associ-
ation between the feature- and outcome-based similar-
ities. In the case of patient survival, we are interested in
whether larger similarities computed from the feature
data reveal a larger proportion of patient pairs with
similar survival times.
Community detection using higher-order sample
similarities
Our analysis is related to the common inference-by-
transitivity technique used in social networks, summa-
rized by the statement ‘a friend of my friend is also my
friend.’ This technique finds cliques of similar patients
in a network by connecting patients that are similar in
the original network and then clustering based on those
similarities. Given samples j and k, and feature vectors
X, we calculate the similarity matrix S(1) (using Ham-
ming similarity (SH
(1)) when the features are binary such
as for mutations and imaging voxels).
Where n is the number of features (e.g. voxels), I(a, b)
is the indicator function that returns 1 if its first argu-
ment equals its second and returns 0 otherwise. Using
this similarity metric, we compute the 2nd-order similar-
ities from the 1st-order matrix. Let m be the number of
samples in the cohort. The second-order metric is
calculated as:


















which is just the definition of the correlation between
the j th row and k th column in S(1) matrix. For higher-
order clustering, the precomputed similarity matrix is
raised to the d power, where d is the order of clustering.
Consensus clustering subsamples both the features
and samples in the data. Each subset of the data is then
clustered using a user–specified clustering algorithm (in
this paper, k-means clustering). The process is repeated
for a user–specified number of iterations (we used
1,000). A consensus matrix is constructed based on the
proportion of iterations in which 2 samples are clustered
together. The final cluster assignments are based on the
consensus matrix. ConsensusClusterPlus clusters matrix
S using a user–specified range of number of clusters (in
this case up to 10 clusters) and the ‘best’ solution is
chosen based on average Silhouette score and on the
relative change in the cumulative distribution function
(CDF) scores calculated by ConsensusClusterPlus. CDF
scores are used to find the number of clusters at which
there is maximum stability between the subsampled
clustering solutions, indicating that the clusters are
representative of true clusters in the data.
Because the ConsensusClusterPlus R package [13]
computes an internal metric prior to clustering and only
takes as input a feature matrix, we would raise the
matrix to the (d − 1) th power and supply this as input
to ConsensusClusterPlus, as the feature matrix. Using
centered Pearson Correlation as the metric is then
equivalent to squaring the feature matrix. In this way,
we tested all even powers of d when using Consensu-
sClusterPlus. For example, our “third-order” solution
effectively uses a fourth-order metric since S(2) is
squared and our “fourth-order” solution is actually a
sixth-order metric since S(3) is effectively squared in-
side the ConsensusClusterPlus package. In this paper,
HOCUS orders refer to the iteration and not the
power of the matrix.
Results
We applied HOCUS to the problem of detecting cancer
subtypes using two very different data modalities – som-
atic mutations and 3D tumor imaging data. Clustering
patient samples by their shared genomic events or
related imaging features may reveal common disease
etiology important for outcome assessment. Yet muta-
tion and imaging data are sparse – sample pairs have
few overlapping events. It is therefore problematic to use
these data as features directly for clustering since simi-
larities calculated from sparse spaces suffer in sensitivity
and specificity [14]. Similarities based on the local neigh-
borhood in a network can be more sensitive because this
approach can capture samples having an indirect coinci-
dence through other samples. We show that the use of
HOCUS for either mutations or imaging data adds
specificity as it produces inferred subtypes that are
biologically– and clinically–relevant that were undetected
by the approaches using lower-order metrics.
Community detection reveals cancer subtypes using
somatic mutation data
The particular ways in which a tumor genome is altered
creates a signature that reflects the type of cell and mu-
tagens involved. Driving events involving specific genes
are associated with certain cancer types. For instance,
BCR-ABL fusions are characteristic of chronic myeloid
leukemia. The question is whether the pattern of muta-
tions within these cells-of-origin can further subdivide
the patient samples into meaningful categories that may
be associated with patient outcomes.
We applied HOCUS to mutation data for 3 TCGA
cancers: high-grade serous ovarian cancer (OV), glio-
blastoma multiforme (GBM), and bladder urothelial
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carcinoma (BLCA). We computed Hamming similarity
over the mutation data for n genes as:
S 1ð Þ : s 1ð Þ j; kð Þ ¼ 1
n
Xn
i¼1 I xi;j; ; xi;k
 
; ð2Þ
where j and k denote two different samples, and xi,j is
the value of feature i for sample j. The Hamming dis-
tance counts the fraction of matching mutated genes for
all sample pairs, resulting in an adjacency matrix of m ×
m samples. We retained for clustering all metrics that
provided a non-redundant set of relations between sam-
ples not captured by lower-order metrics. For higher-
order clustering, we raised the precomputed similarity
matrix S to the d − 1 power, where d is the order of clus-
tering. We then supplied this similarity matrix as the
feature matrix for input to consensus clustering (see
Methods). Figure 1 shows a conceptual example of this
principle– as the order of clustering increases, cliques in
the network emerge and form clusters.
To do this, we identified all kth-order metrics and
lower such that the (k + 1)st metric produced highly
similar relative similarities to the kth metric as measured
by a kernel alignment test [15], (see Additional file 2:
Figure S2). We sought to determine if higher-order
feature-based similarity measures (i.e. those based on
mutations, images etc) had an enrichment for connect-
ing patients with similar survival outcomes compared to
using first-order feature-based measures.
For each tumor type, we clustered the patient sam-
ples based on either Pearson correlation, the first-order
Hamming similarities, or non-redundant higher-order
similarities. We used K-means consensus clustering
[13], for K = 2 to 10, and calculated the degree to which
the solutions separated patients with different outcomes
as a measure of biological relevance. A Kaplan-Meier test
was performed on each clustering solution and the signifi-
cance (-log P-value, log-rank test) was recorded (Fig. 2).
We applied HOCUS to the TCGA GBM dataset con-
taining 283 patients for which 14,910 mutations were
found across 7,874 distinct genes, and found 3 distinct
clusters. Survival differentiation has proven difficult to
achieve in previous analyses of GBM datasets [16, 17],
however the HOCUS results show some difference in
survival between clusters. Note that Pearson correlation
achieves greater difference in survival but must consider
at least ten clusters, which is likely an over-partitioning
of the samples for this data set. Patients in the best
surviving cluster, cluster 1, had low EGFR and TTN
mutation occurrence compared to that of patients in
other clusters; TTN mutations are predominantly in
cluster 3 and EGFR mutations distributed between
clusters 2 and 3. All 14 of the IDH1 mutated tumors
were in cluster 1, as were most (11 of 16) of the ATRX
mutants. The cluster corresponds well with mRNA
cluster 3 (LGr3) from the recent TCGA paper [18].
Thus, the HOCUS clustering using mutations seems to
have been able to tease out a low grade diffuse subtype,
defined by IDH1 mutation status seen in younger indi-
viduals, characterized by the absence of a 1p/19q codele-
tion and a lack of TERT expression and an overall better
prognosis. Furthermore, all 65 samples in cluster 1
have a TP53 mutation (Additional file 3: Figure S3),
whereas there are none in cluster 2 and only 14 (of
105 samples) in cluster 3.
We next applied HOCUS to the TCGA OV dataset
containing 316 patients for which 14,810 mutations in
8,258 genes were reported by the TCGA analysis work-
ing group. For the OV dataset, the first-order solution
found the greatest separation in survival between clus-
tered groups. Higher-order metrics gave different solu-
tions but were comparable with the first-order solution
in separating out patient groups with differences in out-
come. One of the main divisions of the samples shows a
significant difference in overall mutation rate (Additional
file 4: Figure S4). In addition to TP53 mutations, several
genes that are characteristic of passenger mutations were
also predominant in the highly mutated cluster including
TTN, MUC16, and RYR2. Other mutations were sig-
nificantly associated with these clusters, highlighted in
Additional file 4: Figure S4. HOCUS OV clusters correlate
with platinum resistance, which is a survival marker.
These findings were surprising given that the TCGA
OV dataset has posed a significant challenge for analysts
to identify meaningful genome-based distinctions be-
tween the patients [17, 19]. One of the most successful
attempts to date was reported by Hofree et al. [20] in
which patient samples were clustered based on a net-
work diffusion transformation of the mutation data. To
compare the two approaches we ran HOCUS using the
TCGA OV data as filtered by Hofree et al., whereas we
do not filter the mutation datasets. Our results indicated
that comparable survival differences to the NBS ap-
proach could be obtained by using a different metric
(e.g. Hamming distance used here) and higher-order
HOCUS, eliminating the need to introduce prior know-
ledge (Additional file 5: Fig. S5). A similar result was
obtained when applying HOCUS to a TCGA breast co-
hort (see Additional file 6: Section 0.0.4) in which both
the first-order and second-order results revealed similar
survival separation while producing different clustering
solutions. Thus, since the first and second-order
solutions for both OV and BRCA (Additional file 7:
Figure S6, Additional file 8: Figure S7, Section 0.0.4)
gave different clustering solutions but comparable out-
come separation, it is possible that a solution combining
first- and second-order solutions could produce a better
outcome predictor for the patients. Furthermore, since
HOCUS performed better on the OV dataset when
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hypermutated samples and hypomutated genes are ex-
cluded from analysis, it would be beneficial to experi-
ment with more extensive data preprocessing.
We next applied HOCUS to the TCGA BLCA cohort
of 394 patients for which 84,048 mutations were called
based on exome sequencing, covering 15,553 distinct
genes. HOCUS uncovered distinct clusters in BLCA.
Compared to all HOCUS orders, 2nd–order has the lar-
gest separation in survival of the clustered patients. We
note that, like the case for OV, the clusters are associ-
ated with the number of mutations per sample. Indeed,
clustering by mutation rate alone yields comparable sep-
aration in patient outcomes (log-rank test, P <4−10 5;
Additional file 6: Figure S8) as the HOCUS solution.
Since mutation data was the only data used, we searched
for genes with mutations that discriminate the patient
clusters to understand the different underlying etiolo-
gies. Figure 3 shows the top 15 genes associated with
each cluster using a χ2 test of independence (due to over-
lap in the ‘top’ genes for each cluster, 31 genes are shown).
Many of these genes were associated with several can-
cer types, for example LRP1B has been associated with
thyroid, ovarian, renal, and brain cancers [21–23].
Other known oncogenes such as PIK3CA (χ2 test, p-
value 3.6 × 10−4) and TP53 (χ2 test, p-value 3.9 × 10−8)
are also significantly associated with the clusters. Inter-
estingly, the highly mutated BLCA cluster has the best
survival prognosis. On average, cluster 3 patients had a
1.7 to 2.2 times higher survival probability at the 5-year
mark (0.56 compared to 0.33 for cluster 1 and 0.25 for
cluster 2). The 95% confidence interval of the survival
probability at 5-years for cluster 3 patients was (0.45,
0.66) compared to (0.12, 0.38) for cluster 2 patients and
(0.22, 0.43) for cluster 1 patients.
In both cases, a higher rate of TP53 mutations was




Fig. 2 HOCUS in first- through fourth-orders, and Pearson clustering of a GBM c OV and e BLCA survival p-values (log-rank test) vs number of
clusters. b GBM, d OV, and f BLCA Kaplan-Meier plots for selected HOCUS clustering solutions (starred in yellow on the survival p-value plots
(a, c, e). Clusters with fewer than five samples are excluded from the KM analyses
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and a slightly higher rate of smokers was in the category.
However, when we compared our clusters to the TCGA
BLCA clusters, which were generated using mutation and
copy number data with an integrated NMF approach, we
found only a weak correspondence (Additional file 9:
Figure S8(b), χ2 test, p-value 0.128). Thus HOCUS finds a
solution that is distinct from the TCGA–derived sub-
types and one that has a comparable association with
survival outcomes.
We applied HOCUS to the TCGA Pancancer-12
mutations data. Clusters were derived for 3,394 samples
using 313 mutated genes (listed by recent TCGA studies
as high–confidence driver mutations [24, 25]) from
which similarities were calculated. We visualized
the resulting clusters with the Tumor Map tool
(https://tumormap.ucsc.edu/?p=Pancan12.SampleMap&li=5).
Tumor Map projects the HOCUS 2nd-order sample–sample
similarities onto a 2-dimensional map based on the Google
maps framework. Tumor Maps built from mutation data
using Pearson correlations failed to separate samples into
distinct clusters (data not shown), whereas the HOCUS
clusters correlated with many other genomic features and
were able to find subtypes among the samples (Additional
file 10: Figure S9). The subtypes are characterized by
clusters of samples from many tissues of origin. Not
surprisingly, the main difference in most of the clusters is
whether they contain samples with either a TP53 or
PIK3CA mutation. However, of note is that HOCUS
found a pancancer cluster (dashed boxed in Additional file
10: Figure S9) with samples containing both TP53 and
PIK3CA mutations. These tumors either represent cases
in which these two frequently mutated genes are altered
or consist of tumors with higher subclonal heterogeneity
that contain distinct subclones of either TP53 or PIK3CA
mutated cells. In either case, these tumors would be of
particular interest as they harbor two major drivers of
oncogenesis. An attribute enrichment analysis revealed
that samples clustered into the TP53-PIK3CA group are
composed of tumors in later stages on average than those
outside the cluster, consistent with a longer and more
complex evolutionary history for these samples.
In summary, when applied to tissue-specific cohorts,
the mutation-based HOCUS subtyping reveals distinct
sample groupings that appear to be as biologically sig-
nificant, based on survival comparisons, as the original
TCGA expression-derived subtypes, which have been
shown to be highly correlated with histopathology calls.
On the other hand, when applied to a diverse collection
of tumor types that span multiple tissues, the HOCUS-
based mutation clusters identify major divisions that are
not primarily tissue based. Taken together, this suggests
HOCUS could be used in a classification system of the
Fig. 3 Oncoprint showing a subset of mutations in BLCA. Line plots above the oncoprint show the total number of mutations per sample. The
grey dotted lines indicate median mutational frequency across the cohort. This BLCA oncoprint includes genes with the smallest p-values in a χ2
test of independence when compared to mutation rates outside the cluster. We compared each cluster to all others combined
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tumors in which mutation data is incorporated, along
with other data like copy number and gene expression.
Rather than considering mutated genes independently in
this process, as was recently done to build pancancer
decision trees for this data [26], HOCUS clusters could
be used instead, providing potential mutated gene com-
binations for division points like the TP53- PIK3CA sub-
type described here.
Community detection of subtypes using copy number
data
To test the applicability of HOCUS to other data, we
also applied the technique to the clustering of patients
based on Hamming similarity of GISTIC2 discretized
copy number data (see Methods). We applied HOCUS
to TCGA prostate adenocarcinoma (PRAD) copy num-
ber data because prostate cancers are known to harbor
significant copy number events over the evolution of the
tumor including AR amplifications, TMPRSS2-ERG fu-
sions, and even whole genome level events such as chro-
moplexy. We converted the continuous copy number
data to ordinal by using the output of the Broad’s GIS-
TIC2 pipeline [27] that provides gene-level associated
copy number estimates. GISTIC2 scores indicate copy
number aberrations, where 1 indicates low-level and 2
indicates high level amplifications, negative scores indi-
cate the same but deletions rather than amplifications,
and a score of 0 indicates no copy number alterations.
For the TCGA PRAD cohort, survival rates are suffi-
ciently high making patient survival time an inappropri-
ate measure of disease subtype. HOCUS cluster 2
patients have higher Gleason scores, more lymph node
invasion, and higher stage (Additional file 11: Table S1,
Additional file 12: Figure S10), all of which are associ-
ated with disease aggression.
Community detection from magnetic resonance imaging
data
We next applied the HOCUS method to the task of
grouping patients with GBM based on the imaging of their
tumors. Previous imaging studies using MRI have ex-
tracted location and anatomical features to characterize
tumors. Recent imaging studies have utilized MR im-
ages to define patient subtypes for personalized treat-
ment [4, 28, 29]. MR images are 3-dimensional and
contain millions of pixels and human brains have variable
size and shape, making it difficult to compare patients. By
mapping the MR images to the MNI brain atlas (Montreal
Neurological Institute 152 [11]), we were able to compare
patient images, and using HOCUS we were able to find
clinically relevant imaging subtypes.
We applied HOCUS clustering using the GBM voxel
(3-dimensional pixel) data from the TCGA collection of
184 patients with first- and higher-order metrics to find
community structures. MRI data are part of the TCGA
GBM cohort, downloaded from the Cancer Imaging Arch-
ive and processed by Stanford University as described in
Liu et al. [4]. To reduce noise and the size of the MR im-
ages, we first preprocessed the data by filtering to a set of
informative voxels containing tumor in some, but not all,
of the patients (Additional file 13: Figure S11). We re-
moved subsequent analysis all non-informative voxels
with tumor in fewer than 15 individuals (see Additional
file 6: Sec. 0.0.1). We computed sample-to-sample similar-
ities using the remaining voxels and performed higher
order calculations and clustering as described above for
the mutation data (e.g. Hamming distance and Consen-
susClusterPlus were used). Cluster solutions revealed
that the metrics converged by the fourth-order (Add-
itional file 14: Table S2).
We sought to determine which metric based on the im-
aging data best matched up with the observed differences
in patient outcomes. We defined an outcome-based simi-
larity metric by computing all pairwise absolute differ-
ences between the survival time of every pair of patients,
dij = |T(i) − T(j)|, where T(i) is the survival time in days of
patient i. These distances were converted to co-survival
similarities via the linear transform sij ¼ 1m 1−dij
 
, where
m =max{dij} is the maximum absolute differences be-
tween any two patients. We then quantified the correl-
ation between imaging-based similarities and co-survival
similarities using a normalized version of the kernel align-
ment method of Cristianini et al. [15] that calculates a
centered correlation between two full sample-by-sample
similarity matrices. We repeated the kernel alignment
comparison to co-survival for first-order and higher order
HOCUS metrics (Additional file 14: Table S2).
To visualize the results of the kernel alignment com-
parisons, we plotted the probability densities (Fig. 4).
The third- and fourth-order had the highest kernel simi-
larity scores to co-survival as can be verified visually.
We chose the third–order solution because fourth–order
produced similar groupings to the third, and thus the
added complexity of using a higher order was not justi-
fied in this case. Interestingly, second-order had a lower
kernel similarity to co-survival than first-order, illustrat-
ing the benefit of searching several higher order metrics
beyond 2nd–order. We note that second-order HOCUS
stratifies MR images into tumor groups by anatomic
location (Additional file 15: Figure S12(a)). On the other
hand, third-order clusters were driven by a combination
of location and volume. In addition, third-order pro-
duced a larger separation of survival in groups than loca-
tion or volume alone.
Each clustering solution that is based on a different
metric order identifies different characteristics in the
MR images that are associated with survival prognosis.
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While first-order clusters, based on Hamming distance,
align with tumor volume, and second-order with ana-
tomic location (Additional file 15: Figure S12), third-
order clustering captures aspects of both tumor volume
and location (Fig. 5(c-d)). Each solution has statistically
significant separation in survival (Fig. 5(a)), with third-
order having the greatest separation in survival of image
cluster groups. Patients with tumors in the frontal lobe
and which are smaller in volume had significantly better
survival than larger tumors in the lower rear portions of
the brain.
Interestingly, the third-order solution pulled together
patients that made up two separate poor surviving clus-
ters in the second-order solution. To better understand
the third-order subtypes revealed by the imaging data,
we inspected the genetic pathways that distinguish the
poorer surviving subtype from the others using RNASeq
gene expression data available for 184 patients. We com-
puted a differential expression score for each gene to
indicate whether a gene’s expression level was higher or
lower on average in the poorer surviving cluster (cluster
3) relative to the others using the Statistical Analysis of
Microarrays technique [30]. We then connected any
gene with an absolute differential expression higher than
one standard deviation above the average of all genes.
Finally, we retained pathway interactions connecting
only those genes that were both in this set and plotted
them with the Cytoscape viewer [31]. Several pathways
involved in major growth and proliferation signaling
were implicated from these networks as might be
expected (Fig. 6). ERK (MAPK1) was found to be signifi-
cantly overexpressed in cluster 3 tumors along with
JUN-kinase (MAPK8). In addition, AKT1 and PLK1
were also found to be higher in cluster 3, both known to
drive cell cycle progression.
Discussion
To explore how patient-to-patient similarity transforma-
tions influence subtyping, we introduced a method called
Higher-Order Correlations to Uncover Subtypes (HOCUS)
that iteratively calculates higher order metrics using each
similarity space to define patient clusters. HOCUS uses
network connectivity to define groups or ‘communities’ of
patients, related by both direct and indirect connections,
(a) (c)
(b) (d)
Fig. 4 Visualization of sample pair frequencies of image-based metrics compared to survival outcome metric; results on the a first-order, b second-
order, c third-order, and d fourth-order HOCUS. For this visualization only, data was restricted to patients with a death event, then sample–based
pairwise correlations were calculated using 1st-, 2nd-, 3rd-, 4th-order HOCUS metrics as well as difference in the length of survival, in days, between
each pair of patients. In each plot, the conditional density is shown in which the distribution of all sample pairs are depicted as density maps. On the
left-hand side of each plot, a series of plots are shown in which the feature-based measure is divided into five bands of equal size, and differences in
survival time (the outcome metric) are plotted in histograms for those samples restricted to each band. The kernel similarity between the HOCUS
metric and the co-survival metric is shown in the top right corner of each plot
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reinforced by transitive relations in a local subnetwork. The
higher-order metrics incorporate information from local
neighborhoods to assess if two patient samples are related.
In several cases we find that HOCUS provides an im-
provement over methods that use the molecular features
directly to compare samples (Fig. 2). We find that higher
order metrics yield better clusters for BLCA and GBM
patients based on mutations, as well as GBM patients
based on their tumor images.
In the case of BLCA cancer, the second-order metrics
revealed groupings of the patients where tumors with
higher mutation rates are separated from the other
tumors and these patients have an overall better survival
outcome. Most notably, the solutions for BLCA and OV
separate tumors with higher mutation rates from the
others and those patients with higher mutated tumors
have a better survival outlook relative to the other
patients. This result may reflect that highly mutated
tumors are more sensitive to DNA damaging agents (e.g.
cisplatin treatment for OV patients). Alternatively, a
higher mutation rate could increase the number of
neo-antigens present on tumor cell surfaces, helping a
patient’s innate immune system to identify and eliminate
tumor cells that lack immunosuppressive protection
such as through the expression of PD-L1 and/or CTLA4.
Consistent with this idea, recent clinical trials have
found that combining DNA damaging agents with





Fig. 5 HOCUS of GBM MR Images. a P-values of survival separation (log-rank test) for each of the orders of clustering across a range of k clusters.
b Kaplan-Meier plot of the third-order HOCUS clusters. c Images of tumors within each cluster projected onto the MNI brain atlas. Showing sagittal,
coronal, axial views. Brightness of color indicates the number of patients with tumor at a given location. Generated using Slicer [10]. d Violin plot
showing tumor volumes within each third-order cluster. e Molecular (gene expression based) subtypes within the clusters
Fig. 6 PathMark analysis of the poor surviving third-order cluster vs
others. Node size and color indicates differential expression levels
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Alternatively, tumors with higher mutation rates could
reflect a different subtype with an intrinsically distinct
progression pattern. In support of this, we do find a
somewhat higher proportion of papillary BLCA tumors
in the higher mutated cluster (44% of papillary BLCA tu-
mors are in cluster 3), but this association is not signifi-
cant based on a χ2 test.
Medical images are an underused resource that have
vital information [33–38]. A key piece of data conveyed
by imaging is the location of a tumor in the brain, which
can influence when the tumor is detected due to the
tumor affecting certain location-associated brain func-
tions. For example, some tumors may be detected early
because they reside in regions that induce extreme nau-
sea in patients. Furthermore, some tumor locations may
be more resectable than others, such as the frontal lobe
and surface [39]. Thus, imaging data carries important
aspects for subtyping patients according to disease out-
come and treatment selection. In the TCGA data, mo-
lecular subtype is independent of both tumor location
and volume (Additional file 15: Figure S12(c), Additional
file 16: Figure S13).
HOCUS clustering using GBM imaging data automat-
ically clustered the patients into groups by anatomic
tumor location. Our work corroborates that of others in
finding regions associated with poor survival in GBM
patients [4, 40, 41]. We highlight the benefits of using
both genomic and image data in predicting cancer pro-
gression, as imaging data on its own has little predictive
power on its own (Additional file 17: Figure S14), and
recommend combining them in future analysis. We also
show how location influences genomics in GBM as an
independent covariate of molecular subtypes. Both
image and genomic data are key to understanding GBM.
Of note, IGF1 was found to be the most differentially
expressed gene in cluster 3 (Additional file 18: Table S3).
Higher levels of IGF, or its receptor, could point to an
alternate metabolic requirement for these tumors. It
would be interesting to follow up on this observation by
testing if the receptor is present on tumor cell surfaces
to support the possible role of this growth pathway. If
tumor growth is dependent on this pathway than
blocking IGF receptor activity may show benefit in these
patients.
Conclusions
As demonstrated here, community detection approaches
may have merits for subtyping patients when using
sparse data (few events in any single patient sample).
We introduced a visualization method to augment the
quantitative kernel alignment for identifying when a
similarity measure is associated with an outcome meas-
ure of interest. The visualization inspects the distribu-
tion of the patient outcome similarities as a function of
the feature-based similarities. In several cases tested, the
procedure revealed that a higher-order metric was more
associated with survival than non community-informed
metrics. This supports the notion of using community
detection techniques for the analysis of genomics and
imaging data, especially given sparse feature spaces. The
question remains on how to identify the appropriate
order and how many orders should be tested for a given
study, with a given type of data set, especially in a situ-
ation where outcome based information is unavailable.
HOCUS is applicable to both binary (i.e. mutation and
voxel) data and ordinal data (e.g. CNV). HOCUS is sim-
ple and flexible enough to be used wherever a suitable
similarity metric between individuals can be generated,
even for non-sparse data such as expression or methyla-
tion data. As we have shown, its application has the po-
tential to reveal groupings missed when using standard
metrics. HOCUS code is available at github.com/graim/
HOCUS.
Additional files
Additional file 1: Figure S1. Alternative similarity metrics used to
compare patients. (a) P-values of survival differences (log-rank test)
between clusters for each similarity metric over a range of clusters, (b)
tumor volumes of second-order TFIDF clusters, (c) molecular subtypes
within each second-order TFIDF cluster. (d) Tumors volumes of Jaccard
clusters, (e) barplot of molecular subtypes by Jaccard cluster, (f) brain
images of Jaccard clusters, and (g) a ribbon plot showing the changes
in cluster membership when using different similarity metrics on the
same data. (EPS 22877 kb)
Additional file 2: Figure S2. Visualization of association between
mutation-based and outcome-based similarity measures for TCGA co-
horts: a) OV, b) BLCA, and c) GBM. For this visualization only, data was
restricted to patients with a death event, then pairwise correlations were
calculated in each feature space (Pearson, 1st-, 2nd-, 3rd-order HOCUS) as
well as difference in the length of survival, in days, between each pair of
patients. A series of plots, one for each metric (Pearson correlation,
hamming similarity, or higher-order) for three different tumor analyses.
In each plot, the joint density is shown in which the distribution of all
sample pairs are depicted as density maps. On the left-hand side of each
plot, a series of plots are shown in which the feature-based measure is
divided into five bands of equal size, and differences in survival time (the
outcome metric) are plotted in histograms for those samples restricted to
each band. The number in the top right corner of each plot is the kernel
similarity between the HOCUS metric and the co-survival similarity. In
every case tested, a higher-order metric could be found that had a
positive association with the survival similarity metric, whereas Pearson
correlation, based on the original features, had seemed to have a low
and sometimes negative association. For example, the surprising negative
association of the Pearson-based first-order measure is evident where
most highly correlated sample pairs actually show an appreciable in-
crease in samples with very different survival outcomes (seen as the intro-
duction of extra ”modes” in the top histograms). For BLCA and GBM
cohorts the higher-order clustering solutions revealed subtypes with better
survival separation than first-order metrics. For OV, the higher-order metrics
performed comparably with Pearson just outperforming. (EPS 159131 kb)
Additional file 3: Figure S3. (a) Violin plot showing mutational
frequency per cluster and (b) Oncoprint showing a subset of mutations
in GBM that are associated with cluster 1 via a χ2 test and are mutated in
at least 10 samples. Line plot above the oncoprint shows the total
number of mutations per sample, and the grey line indicates median
mutational load across the entire cohort. We show 5 frequently mutated
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genes that are associated with GBM mutations HOCUS result via a χ2 test
of independence, cluster 1. (EPS 348 kb)
Additional file 4: Figure S4. Oncoprint showing a subset of mutations
in OV. Line plots above the oncoprint shows the total number of
mutations per sample. The grey dotted lines indicate median mutational
load across the cohort. A combination of the most frequently mutated
genes in the OV cohort (colored black) and the genes significantly
associated with any 1st-order HOCUS cluster through a χ2 test of inde-
pendence are shown. Colors in the oncoprint indicate which cluster the
mutation is associated with. TTN, a known passenger mutation, is associ-
ated with clusters 2 and 3. (EPS 971 kb)
Additional file 5: Figure S5. Comparison to Network-Based Stratifica-
tion [6] using the TCGA OV data used in their publication, and the same
filtering. (JPG 528 kb)
Additional file 6: Supplemental text. (DOC 132 kb)
Additional file 7: Figure S6. Oncoprint showing the HOCUS BRCA
clusters and associated mutations. (EPS 5745 kb)
Additional file 8: Figure S7. Visualization of the BRCA copy number
clusters and their correlation with the mutation-based subtypes from
HOCUS. Heatmap made using the UCSC Cancer Genomics Browser [7],
showing TCGA CNV subtypes and CNV alterations in the HOCUS clusters.
(JPG 531 kb)
Additional file 9: Figure S8. (a) KM plot where samples are grouped by
overall mutational frequency. P-value 4.7e − 05 (compared to HOCUS p-
value 1.59e − 05), and (b) Alluvial diagram showing the difference in
HOCUS 1st-order BLCA clusters and the TCGA-defined clusters based on
mutation and CNV data. P-value 0.128 in a χ2 test of independence. This
diagram compares the 125 samples that are defined in both cluster sets.
(EPS 45294 kb)
Additional file 10: Figure S9. Screenshot of the interactive Tumor Map
visualization, showing HOCUS applied to the TCGA Pancan-12 mutation
data. Each point is one tumor sample, which we have color-coded by tis-
sue type. A dotted box highlights the cluster of samples that have both
PIK3CA and TP53 mutations, which are usually mutually exclusive. (EPS
751 kb)
Additional file 11: Table S1. P-values from χ2 tests on all the data
types. (XLSX 41 kb)
Additional file 12: Figure S10: (a) Pathology T stage of the HOCUS
copy number clusters. (b) Enrichment of Gleason scores in the HOCUS
clusters. Scores are normalized by column and color represents
percentage of the cluster with a given combined Gleason score. (c)
Boxplot of the number of lymph nodes each cluster’s samples have
invaded. (EPS 221 kb)
Additional file 13: Figure S11. (a) Heatmaps of tumor image, where
each heatmap shows one slice of the brain and is colored by the
overlapping tumors between patients in the cohort before image
filtering. Each heatmap shows one slice of the brain. From top left to
bottom right, the slices start at the top of the head at show progressively
lower portions of the brain. (b) Log change in tumor volume as MR
images are filtered at different thresholds. (c) Lefthand plot shows the
number of samples whose tumors are completely masked by filtering,
and the righthand plot shows the per-patient tumor volume before and
after filtering. Each dot represents one patient. (d) As in (a), these are
heatmaps of the tumor images after filtering. (EPS 19672 kb)
Additional file 14: Table S2. Kernel similarity scores between each
HOCUS feature space, survival in days, and age. (XLSX 610 kb)
Additional file 15: Figure S12. (a) Sagittal, coronal, and axial views of
the tumors within each image cluster (b) Violin plots of tumors volumes
for each cluster. (c) Comparison to molecular subtypes defined by TCGA.
(d) Kaplan-Meier plot of image clusters, showing clusters 3 and 4 to have
poorer overall survival. (e) Consensus clustering matrices for 2nd- and
3rd-order HOCUS clusters, connected by an alluvial diagram showing that
the majority of patients in 2nd-order clusters 3 and 4 (the poor survivors)
make up the 3rd-order cluster 3. (EPS 15887 kb)
Additional file 16: Figure S13. (a-c) Patients grouped on tumor
volume and (d-f) by TCGA defined molecular subtypes for MR image
patients. (a) Images of patient tumors grouped by tumor volume (b)
molecular subtypes (c) KM survival. (d) Images of patient tumors grouped
by molecular subtype, (e) tumor volume per group, (f) KM survival. (EPS
6584 kb)
Additional file 17: Figure S14. KM plot of survival when patients are
grouped by anatomic location of the tumor. Annotations indicate
laterality (right/left) and lobes (parietal, occipital, frontal, temporal).
(JPG 51 kb)
Additional file 18: Table S3. P-values from χ2 tests between image
clusters of all types and clinical covariates. (XLSX 51 kb)
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